(Il Sole 24 Ore Radiocor) - Milano, 13 gen - American-Canadian eyecare company Bausch + Lomb said it has acquired Whitecap Biosciences, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA).

Financial details of the acquisition, which Bausch + Lomb said expands its clinical-stage pipeline, were not disclosed.

Whitecap Biosciences was founded in 2015 to develop novel therapies for ophthalmic diseases with a focus on glaucoma,.

GA and other serious eye diseases.

(RADIOCOR) 13-01-25 18:41:30 (0505) 5 NNNN